Lockheed Martin and Johnson & Johnson released their latest earnings reports before opening bell this morning. Lockheed Margin reported adjusted earnings of $3.25 per share on $13.75 billion in revenue. Analysts had been expecting the defense contractor and airplane manufacturer to report $3.05 per share in earnings and $13.03 billion in revenue. In last year’s fourth quarter, the company reported $11.52 billion in revenue.
Johnson & Johnson reported $1.58 per share in adjusted earnings, marking a 9.7% year over year increase, and $18.11 billion in revenue. Analysts had been expecting the consumer products company to report $1.56 per share in adjusted earnings and $18.26 billion in revenue. In the previous year’s fourth quarter, the company posted $17.81 billion in revenue.
Berkshire Hathaway’s Buffett On Diversification
In his 2014 letter preview, Buffett states that, far from being a weak choice, indexing can often achieve investor's goals far more easily than complicated picking strategies. This is a special guest post by Robert R. Johnson, Ph.D., CFA, CAIA. He is a full professor of finance at the Heider College of Business at Creighton Read More
Lockheed Martin shares fall
Lockheed Martin said aeronautics sales rose to $5.41 billion from $4.38 billion in the same quarter a year ago. The company’s GAAP earnings rose to $3.35 per share from $3.01 per share in the year-ago quarter.
Lockheed Martin expects revenue for this year to be between $49.4 billion and $50.6 billion, compared to the consensus of $49.6 billion. It expects earnings to fall between $12.25 and $12.55 per share, compared to the consensus of $12.88 per share.
Shares of Lockheed Martin declined by as much as 1.47% to $253.70 in premarket trading this morning.
Johnson & Johnson shares fall
Johnson & Johnson’s net earnings rose to $1.38 per share from $1.15 per share in the fourth quarter of 2015. Domestic sales rose 2.6% year over year, while international sales ticked upward by 0.6% on the back of currency headwinds amounting to 1.3%. Consumer sales rose 3.4% to $3.4 billion in the fourth quarter, while Pharmaceutical sales rose 2.1% to $8.2 billion. Medical Devices sales increased -.2% to $6.4 billion.
The company’s 2017 full-year sales outlook stands between $74.1 billion and $74.8 billion, marking between 4% and 5% operational growth. Johnson & Johnson expects adjusted earnings to be between $6.93 and $7.08 per share for the full year.
Johnson & Johnson shares ticked downward by as much as 1.67% to $112.01 in premarket trades.